Gut Brain Axis Therapeutics is thrilled to announce the successful closing of an $8,000,000 funding round鈥攁 monumental step forward in our mission to revolutionize autism treatment through innovative Microbial Transplant Therapy (MTT). Founded by renowned experts including Professor James B. Adams and Professor Rosa Krajmalnik-Brown from Arizona State University, along with Professor Alex Khoruts and Professor Michael Sadowsky from the University of Minnesota, our company centers its efforts on addressing the often-overlooked gastrointestinal challenges experienced by individuals with Autism Spectrum Disorder. Nearly 40% of children and adults with autism struggle with chronic GI issues such as constipation, diarrhea, bloating, and pain, commonly linked to abnormal gut bacteria. Our intensive and patented approach to MTT has already delivered promising early outcomes, with initial studies demonstrating a significant 80% reduction in gastrointestinal symptoms and measurable improvements in core autism symptoms over time.
This latest funding round is critical in advancing our next phase of research: a Phase 3 FDA approved, double-blind, placebo-controlled trial designed to further assess the efficacy and safety of MTT for autism. With this significant investment, we will expand our clinical trials, enhance research infrastructure, and facilitate broader data collection to pave the way for a transformative treatment modality that addresses both the neurological and gastrointestinal facets of autism. By bridging cutting-edge microbiome science with clinical innovation, Gut Brain Axis Therapeutics is committed to improving the quality of life for countless individuals and families impacted by autism. We are excited for the journey ahead and look forward to collaborating with the medical and research communities as we continue to challenge conventional treatment paradigms and deliver hope where it is needed most.
